Table 2.
Drug regimen and virological Response of the study population
| IFN Group (SOF+IFN+RBV) n=60 |
DAC Group (SOF+DAC+RBV) n=73 |
|
|---|---|---|
| RVR | 59 (98.3%) | 71 (97.3%) |
| ETR | 56 (100 %) | 73 (100 %) |
| SVR 12 | 59 (98.3%) | 70 (95.9%) |
| Non-responders | 1 (1.6%) | 3 (4.1%) |
| 3-months treatment | 59 (98.3%) | 71 (97.3%) |
| 6-months treatment | 1 (%) | 2 (2.7%) |
Dac: Daclatasvir, ETR: End of treatment response, IFN: interferon, RBV: Ribavirin RVR: Rapid Virological Response, SOF: Sofosbuvir, SVR12 Sustained Virological Response at 12 weeks